| Fiscal period | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Period End Date | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 |
|---|
| Net Sales | 41,950.00 | 40,109.00 | 43,653.00 | 43,075.00 | 34,608.00 | 31,904.00 | 30,578.00 | 27,390.00 | 20,853.00 | 20,405.00 |
| Total Revenues | 41,950.00 | 40,109.00 | 43,653.00 | 43,075.00 | 34,608.00 | 31,904.00 | 30,578.00 | 27,390.00 | 20,853.00 | 20,405.00 |
| Cost of Products Sold | 18,706.00 | 17,975.00 | 19,142.00 | 18,537.00 | 15,003.00 | 13,231.00 | 12,706.00 | 12,337.00 | 9,024.00 | 8,747.00 |
| Amortization of intangible assets | 1,878.00 | 1,966.00 | 2,013.00 | 2,047.00 | 2,132.00 | 1,936.00 | 2,178.00 | 1,975.00 | 550.00 | 601.00 |
| Research and development | 2,844.00 | 2,741.00 | 2,888.00 | 2,742.00 | 2,420.00 | 2,440.00 | 2,300.00 | 2,235.00 | 1,422.00 | 1,405.00 |
| Acquired in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling, general and administrative | 11,697.00 | 10,949.00 | 11,248.00 | 11,324.00 | 9,696.00 | 9,765.00 | 9,744.00 | 9,117.00 | 6,672.00 | 6,785.00 |
| Total Operating Cost and Expenses | 35,125.00 | 33,631.00 | 35,291.00 | 34,650.00 | 29,251.00 | 27,372.00 | 26,928.00 | 25,664.00 | 17,668.00 | 17,538.00 |
| Operating earnings | 6,825.00 | 6,478.00 | 8,362.00 | 8,425.00 | 5,357.00 | 4,532.00 | 3,650.00 | 1,726.00 | 3,185.00 | 2,867.00 |
| Interest expense | 559.00 | 637.00 | 558.00 | 533.00 | 546.00 | 670.00 | 826.00 | 904.00 | 431.00 | 163.00 |
| Interest income | 344.00 | 385.00 | 183.00 | 43.00 | 46.00 | 94.00 | 105.00 | 124.00 | 99.00 | 105.00 |
| Other income (expense), net | 376.00 | 479.00 | 321.00 | 277.00 | 103.00 | 191.00 | 139.00 | 1,251.00 | (945.00) | 281.00 |
| Net foreign exchange gain (loss) | 27.00 | (41.00) | (2.00) | (1.00) | 8.00 | (7.00) | (28.00) | 34.00 | (495.00) | 93.00 |
| Income (Loss) from TAP Pharmaceutical Products Inc. joint venture | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain (loss) on extinguishment of debt | -- | -- | -- | -- | -- | (63.00) | (167.00) | -- | 0.00 | 0.00 |
| Earnings before taxes | 7,013.00 | 6,664.00 | 8,306.00 | 8,211.00 | 4,968.00 | 4,077.00 | 2,873.00 | 2,231.00 | 1,413.00 | 3,183.00 |
| Taxes on earnings | (6,389.00) | 941.00 | 1,373.00 | 1,140.00 | 497.00 | 390.00 | 539.00 | 1,878.00 | 350.00 | 577.00 |
| Income (loss) from Continuing Operations | -- | -- | 6,933.00 | 7,071.00 | 4,471.00 | 3,687.00 | 2,334.00 | 353.00 | 1,063.00 | 2,606.00 |
| Earnings (Loss) from Discontinued Operations, net of taxes | -- | -- | -- | -- | 24.00 | -- | 34.00 | 124.00 | 321.00 | 65.00 |
| Gain on sale of discontinued operations, net of tax | -- | -- | -- | -- | -- | -- | -- | 0.00 | 16.00 | 1,752.00 |
| Net earnings allocable to Common Units | 13,402.00 | 5,723.00 | 6,933.00 | 7,071.00 | 4,495.00 | 3,687.00 | 2,368.00 | 477.00 | 1,400.00 | 4,423.00 |
| Earnings Per Share (Basic) - Cont Ops | -- | -- | 3.94 | 3.97 | 2.51 | 2.07 | 1.32 | 0.20 | 0.71 | 1.73 |
| EPS (Basic) : Disc Ops | -- | -- | 0.00 | -- | 0.01 | -- | 0.02 | 0.07 | 0.23 | 1.21 |
| Basic earnings per common share | 7.67 | 3.28 | 3.94 | 3.97 | 2.52 | 2.07 | 1.34 | 0.27 | 0.94 | 2.94 |
| Earnings Per Share (Diluted) - Cont Ops | -- | -- | 3.91 | 3.94 | 2.49 | 2.06 | -- | 0.20 | 0.71 | 1.72 |
| Earnings Per Share (Diluted) - Disc Ops | -- | -- | 0.00 | -- | 0.01 | -- | 0.02 | 0.07 | 0.23 | 1.20 |
| Diluted earnings per common share | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 | 1.33 | 0.27 | 0.94 | 2.92 |
| Average Number of Common Shares Outstanding (Basic) | 1,740.00 | 1,740.00 | 1,753.00 | 1,775.00 | 1,773.00 | 1,768.00 | 1,758.00 | 1,740.00 | 1,477.00 | 1,496.00 |
| Average Number of Common Shares Outstanding (Diluted) | 1,748.00 | 1,749.00 | 1,764.00 | 1,789.00 | 1,786.00 | 1,781.00 | 1,770.00 | 1,749.00 | 1,483.00 | 1,506.00 |